Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

Mohamed L. Sorror; Barry Storer; Brenda M. Sandmaier; Leanthe Braunert; Ginna G. Laport; Thomas Chauncey; Christopher Bredeson; Richard T Maziarz; Michael A. Pulsipher; Edward Agura; Michael T. Maris; Lars Vindelov; Firoozeh Sahebi; Peter McSweeney; Benedetto Bruno; Amelia Langston; Rainer F. Storb; and David G. Maloney